Please login to the form below

Not currently logged in
Email:
Password:

Purdue looks to Merck for new CEO

Mark Timney will lead pain specialist
Mark Timney, Purdue Pharma

Purdue Pharma has appointed Merck & Co veteran Mark Timney as CEO, replacing John Stewart who retires.

Timney spent 15 years at Merck, where he most recently served as president of global primary care.

His previous roles include president of Merck US, during which time he helped to launch the hepatitis C drug Victrelis (boceprevir) and led the acquisition of ophthalmology company Inspire Pharmaceuticals.

Prior to moving to the US, Timney served as Merck's country manager in Korea and then Japan following a period in Australia.

Before joining Merck, he spent eight years in sales and marketing at a number of pharmaceutical companies, including Zeneca in New Zealand, ICI Pharmaceuticals in Australia, and Roussel Labs in the United Kingdom

Dr Raymond Sackler, co-founder and board member of pain specialist Purdue, said they had found a “proven leader” in Timney.

"I am confident that his capabilities and experience, coupled with Purdue's culture of excellence, will grow our business and strengthen our healthcare industry leadership,” said Sackler.

30th January 2014

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics